Mutations, Sequencing, Resistance: Advances and Updates in Chronic Lymphocytic Leukemia

To participate in this activity, please:

The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been transformed with the introduction of targeted therapies, providing the opportunity to utilize minimal residual disease (MRD) as an indicator of treatment response and prognostic marker. This 1-hour online, self-directed activity explores the treatment landscape through 9 complex, real-world clinical decisions to advance clinicians’ understanding and application of best evidence and practices. The unique educational design actively engages learners with content, as faculty provide an in-depth rationale for each decision, based on their extensive experience.

Course Credit:

1 AMA PRA Category 1 CreditTM


Opens: 2024-02-29
Closes: 2025-02-28

Target Audience:

This activity was developed for pathologists, hematologists, and medical oncologists.

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Eisai, Genentech, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Sameer A. Parikh, MBBS

    Associate Professor of Medicine
    Assistant Professor of Oncology
    Department of Internal Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

Learning Objectives

  • Appreciate the prognostic significance and latest evidence for testing for del(17p) and TP53 alterations in chronic lymphocytic leukemia (CLL)
  • Recognize the impact of minimal residual disease assessment in contemporary CLL practice
  • Acknowledge the mechanisms of resistance to Bruton’s tyrosine kinase (BTK) inhibitors in CLL
  • Assimilate clinical data into clinical practice for available and emerging therapies for patients who develop BTK inhibitor-resistant disease

Faculty Disclosures

Sameer A. Parikh, MBBS

Advisory Board: Amgen, Ascentage Pharma, AstraZeneca, BeiGene, Genentech, Janssen, Merck, MingSight Pharmaceuticals, Pharmacyclics